Earnings Updates, In Brief: Vitae, OncoGenex, Cara
Executive Summary
Vitae and partner Boehringer Ingelheim to start over in Alzheimer’s with new compound, shelving lead drug due to skin reactions. OncoGenex sees subgroup data providing a potential niche indication for custirsen, while Cara is ready to begin Phase III with its intravenous candidate for post-surgical acute pain.